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The eleventh scientiWc conference progress in vaccination
against cancer (PIVAC-11) was held 10–13 October in
Copenhagen, Denmark. Currently, the success of cancer
immunotherapy as treatment modality is improving and
newly approved drugs and immunotherapies are showing
encouraging clinical results. To be eVective, cancer vacci-
nation needs to stimulate powerful immune responses
against speciWc targets as well as overcome the barriers that
cancer cells use to protect themselves. Especially, new
drugs (i.e. Ipilimumab) have demonstrated that targeting
suppressive elements leads to highly improved clinical out-
come. PIVAC-11 was characterized by much optimism and
interesting new data on how to improve cancer vaccination
were presented. Talks were given on aspects of combina-
tion therapies, genetic vaccinations, combinations of che-
motherapy and immunotherapy and tumor immune escape
mechanisms.
The conference opened with a keynote evening, address-
ing the use of adoptive transfer of T cells in cancer patients.
Patrick Hwu (Houston, TX, USA) presented the latest
results of a phase II clinical trial based on adoptive cell
therapy (ACT) with tumor inWltrating lymphocytes (TILs)
at MD Anderson Cancer Center (MDACC). Thus far, 41
melanoma patients have been treated, 2/38 (5%) showed
complete responses (CR) and 16/38 (42%) had a partial
response (PR). The frequency of CD8+ T cells but not
CD4+ T cells in TILs correlated with better clinical
response (CR/PR). Intriguingly, the frequency of CD8+ T
cells with surface expression of the inhibitory receptor “B
and T Lymphocyte Attenuator” (BTLA) in TILs also corre-
lated with better prognosis. Hwu pointed out that a major
rate-limiting step in ACT seems to be the ineYcient T-cell
migration to tumors. His group has shown that melanoma
speciWc T cells do not express CXCR2—the receptor for
CXCL1 and CXCL8 expressed in melanomas, and the
insertion of genes encoding this chemokine receptor into
TILs may improve T-cell migration and result in better CR.
Hwu presented data from murine model studies showing
that gp 100-speciWc T cells transduced with CXCR2 (recep-
tor for CXCL1 and IL-8) have enhanced accumulation in
tumors, delay tumor growth and lead to improved survival.
Furthermore, the combination of anti-PD-1 and BRAF
inhibitors with ACT treatment is currently being investi-
gated in mice. Interestingly, data showed that increased
anti-tumor activity and enhancement of migration of T cells
into tumors could be found.
Next, Ton Schumacher (Amsterdam, Holland) demon-
strated—by analyses of more than 30 TIL products—that
both the magnitude and frequency of tumor-speciWc T cells
was very low in TILs. The group used a high throughput
multimer-based method for T-cell detection (“combi-coding”)
and analyzed the presence of T cells speciWc for a panel of
145 HLA-A2-restricted known CD8+ T-cell melanoma-
associated epitopes [from both melanocyte diVerentiation
(MD), cancer testis (CT) and overexpressed (OE) antigens].
It turned out that every patient had a unique combination of
antigen-speciWc T cells. In addition, he demonstrated that
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found in the periphery 1 month post-therapy. Indeed, TIL
therapy seemed to broaden the melanoma speciWc T-cell
repertoire as speciWc T cells found in TIL products and
PBMC 1 month later were only rarely seen in pre-treatment
PBMC. Interestingly, only the presence of T-cell reactivity
against CT antigens showed a trend towards correlation with
CRs (p = 0.12). Schumacher ended this section by mentioning
that it will also be worthwhile to use this technology to exam-
ine the immunological consequences of future clinical
approaches in melanoma such as the combination of Ipi-
limumab (anti-CTLA-4) and Vemurafenib (mutant BRAF
inhibitor). In his second part, Schumacher elegantly demon-
strated, by use of in vivo imaging, how sites of former infec-
tion or vaccination contained tissue-resident memory CD8+ T
cells. These cells were dendritic cell shaped and seemed to
function as skin patrols with crawling behaviour. Recognition
of relevant antigen led to cessation of migration and the shape
of the cells rounded up at the site of antigen presentation.
The conference now continued with other aspects of cell-
based therapies and in addition to the use of TILs, T cells can
also be manipulated before reinfusion to become tumor reac-
tive. Marc Schmitz (Dresden, Germany) presented data from
a clinical trial where chronic myeloid leukemia (CML)
patients received a prophylactic infusion of in vitro generated
tumor-reactive T cells after hematopoietic cell transplanta-
tion (HCT) was shown to lead to induction of peptide-spe-
ciWc cytotoxic CD8+ T cells in 7/14 CML patients.
Leukemia-speciWc CD8+ T cells were generated by use of
donor-derived dendritic cells loaded with leukemia antigens
such as PR3-, WT1- and/or BCR-ABL-derived peptides.
Schmitz demonstrated for the Wrst time that prophylactic
infusion of leukemia-speciWc T cells after HCT is feasible
and safe and found that the probability of overall and molec-
ular relapse-free survival was 93 and 49%, respectively. A
new approach to adoptive immunotherapy was presented by
Alexei Kirkin (Hørsholm, Denmark). By treating activated
Th1 CD4+ T cells with a DNA-demethylating agent (5-aza-
2-deoxycytidine) expression of cancer/germline (CG) pro-
teins was induced. These CD4+ T cells were then used
instead of DCs for enrichment in vitro of autologous cyto-
toxic CD8+ T cells. A phase I trial is currently being carried
out, 13 prostate cancer patients have received a single dose of
cytotoxic lymphocytes with no signs of toxicity and 9 have
had stabilization or decrease in PSA levels.
As a result of thymic selection, natural antitumor T cells
exhibit weak aYnity for their cognate peptide¡MHC com-
plexes and are therefore at a distinct disadvantage com-
pared to their pathogen-speciWc counterparts. Andy Sewell
(CardiV, UK) discussed three novel strategies to overcome
this obstacle. First, it was shown that altered peptide
ligands could be used to inXuence the quality of a primed
T-cell response through a process called TCR-optimised
peptide skewing of the repertoire of T cells (TOPSORT).
TOPSORT can selectively prime only the most eVective TCR
clonotypes to produce an overall more eYcient response to
tumor at the single cell level than priming with the natural
antigen. Secondly, it was shown that T cells transduced with
enhanced antitumor TCRs with aYnities like the very best
antiviral TCRs were more sensitive to antigen density and bet-
ter at recognizing real tumor cells than T cells displaying
equivalent natural aYnity TCR. Thirdly, collaboration with
Immunocore Ltd., has demonstrated high aYnity soluble TCR
fusion reagents consisting of an anti-CD3 scFV domain and
monoclonal TCRs can redirect polyclonal T cells to lyse
tumor cells and induce regression of established tumor. These
‘ImmTAC’ molecules are currently in phase I clinical trial.
The engineering of T cells with a recombinant chimeric
antigen receptor (CAR) composed of antibody binding
domains connected to domains that activate T cells is a
novel and promising approach for the treatment of cancer
that has already demonstrated clinical activity in chronic
lymphocytic leukemia patients. Recent work by Hinrich
Abken (Cologne, Germany) suggest CD20 to be a marker
for melanoma stem cells that may account for <2% of all
neoplastic cells. In mice cytotoxic T cells engineered with a
CD20-targeting CAR eliminated this minor subset of cells
as well as induced regression of whole melanoma lesions.
The power of CAR T cells in an example of gastrointestinal
carcinoma could be more improved by inducing IL-12 upon
CAR engagement. He elegantly showed how antitumor-
induced responses in mice mediated by macrophages are
crucial for tumor control in this setting. This novel treat-
ment by “T-bodies” with inducible IL-12 holds promise for
eVective treatment of malignant diseases.
Dendritic-based clinical vaccinations are currently being
explored in clinical trials and new strategies were presented
at the meeting. Gustav Gaudernack (Oslo, Norway)
reported on their Wrst phase I/II clinical trial targeting brain
tumor stem cells by vaccination with monocyte-derived
dendritic cells (DCs) transfected with autologous glioblas-
toma stem cell mRNA. He demonstrated that glioblastoma
stem cells, a subpopulation of transformed cells that might
be responsible for tumor propagation, resistance to conven-
tional therapies and tumor recurrence, can be cultured in
vitro in the majority (35/44) of patients and form neuro-
spheres. In addition, in vitro neurosphere formation is an
independent negative prognostic factor in glioblastoma.
Treatment with transfected monocyte-derived DCs, given
in combination with temozolomide and radiotherapy, gen-
erated tumor-speciWc immune responses in all treated
patients, with no signs of severe toxicities. Gaudernack
showed how, compared to disease-matched controls,
patients had a 3.5 times longer progression free-survival.
Another subset of DCs—the plasmacytoid (pDCs)—are
also currently being used in clinical trials. To this end,123
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the Wrst phase I clinical trial using FSME-IMMUN®
matured tumor-peptide-loaded pDCs isolated with the
Clini-MACS and then injected into stage IV melanoma
patients. Fifteen patients were treated and pDC vaccination
appeared to be feasible and safe. Importantly, it was shown
by use of scintigraphic imaging that upon injection pDCs
migrated to distant lymph nodes.
The combination of vaccination with chemotherapy was
reported by Leisha Emens (Baltimore, MD, USA). She
investigated how to take advantage of simultaneous or
sequential administration of cancer vaccines and conven-
tional chemo- or targeted therapeutics by fostering immune
responses for breast tumor rejection. By using the paired
FVB/N—neu N mouse model of HER-2+ breast tumors (no
immune tolerance/immune tolerance), they investigated
mechanisms of synergy and antagonism between HER-2-
targeted, granulocyte–macrophage colony-stimulating fac-
tor (GM–CSF)-secreting vaccines and sequentially-com-
bined low dose of cyclophosphamide with doxorubicin or
anti HER-2 monoclonal antibodies. This revealed a syner-
gistic activity between the vaccine and chemotherapies in
both cases. Indeed, she showed how these drug combina-
tions boosted vaccine-induced immunity. She subsequently
discussed the results of two clinical trials demonstrating the
safety and bioactivity of these combination vaccine
approaches in both metastatic HER-2-negative (cyclophos-
phamide and doxorubicin) and HER-2-positive (cyclophos-
phamide and the anti-HER2 antibody trastuzumab) breast
cancer. Another example of combination strategies was
presented by Esteban Celis (Tampa, FL, USA) demonstrat-
ing that cancer vaccines via the co-administration of pep-
tide vaccines with Poly-IC and anti-CD40 mAb (so-called
TriVax) and a newer approach solely using peptide and
Poly-IC (BiVax) can induce powerful T-cell responses in
mice that lead to signiWcant anti-tumor eVects. However,
the success of the BiVax strategy depends on the physical
characteristics of the peptide; he believes that only those
peptides that are able to form a complex with the Poly-IC
(via ionic or hydrophobic interactions) may exhibit this
high immunogenicity. This knowledge can be used to mod-
ify non-immunogenic peptides into high immunogenic
variants. Furthermore, he presented interesting data
showing that the success of peptide vaccination in mice is
inhibited by IFN-. Tumors exposed to IFN- evade CTLs
by expressing non-cognate major histocompatibility com-
plex class I molecules, which limit T-cell activation and
eVector function. Indeed, adjuvants can be an essential part
of an eVective vaccine and Else Marie Agger (Copenhagen,
Denmark) presented a new generation adjuvant system that
involves a delivery vesicle to promote uptake and presenta-
tion of a vaccine antigen. The cationic liposomal adjuvant
CAF01 has been shown to induce both humoral and cellular
responses and is currently used in several phase I clinical
trials. Incorporation of the TLR3 ligand polyinosinic:poly-
cytidylic acid (pI:C) in the CAF01 lipids was shown to
induce CD8+ T cells to high levels, and these T cells were
demonstrated to be cytolytic.
The use of a DNA vaccine strategy encoding CTL epi-
topes within the CDR of an antibody (ImmunoBody™) was
presented by Lindy Durrant (Nottingham, UK). The Immu-
noBody DNA vector platform stimulates antitumor activity
using mAbs genetically engineered to present CTL epitopes
and eVectively targeting DCs by cross presentation via the
CD64 (FcgR1) receptor on DC. Lindy elegantly showed
that vaccination with Immunobody™ induces high fre-
quency and moderate avidity tumor-speciWc CD8+ and
CD4+ responses in mice with high cancer killing capacity.
Interestingly, these responses could not be increased by the
APCs activator Homspera® but this compound could
enhance anti-tumour responses. Recently, a phase I/II trial
in stage III/IV melanoma involving 4 UK centers was
started.
The immunological monitoring of responses after clini-
cal vaccination and correlation to outcome is essential for
our future understanding of the interplay between vaccina-
tion, anti-tumor immunity and immune suppressive
mechanisms. As demonstrated by Cécile Gouttefangeas
(Tübingen, Germany) multipeptide vaccination including
both CTL and Th epitopes (phase I/II trial) induced periph-
eral T cells against the majority of the peptides used for
vaccination in 37 prostate cancer patients. Prostate speciWc
antigen (PSA) doubling times were measured as a marker
for tumor response, and interim results showed that patients
receiving TLR7/8 adjuvants had a better clinical course.
Furthermore, she presented a status report on the “cancer
immunotherapy immune-guiding program” (CIP) which
currently has 43 participating laboratories. The mission of
CIP is to harmonize and increase the quality of in vitro
monitoring assays used in diVerent laboratories. One instru-
mental tool to reach this objective is to organize regular
international proWciency panels for T-cell assays. The
upcoming proWciency panels will fall in three categories.
(1) Annual large scale service panels for performance feed-
back, (2) small scale development panels for speciWc ques-
tions/tests and (3) small scale exploratory panels for testing
new assays. Graham Pawelec (Tübingen, Germany) pre-
sented the immunological monitoring data of a pilot RNA
vaccination trial in melanoma. In this study, stage III and
IV melanoma patients were vaccinated with an RNA vac-
cine encoding the antigens NY-ESO1, Survivin, MAGE-
A3 and Melan-A. The immune monitoring showed a sig-
niWcant association between survival of unresectable stage
IV patients and the presence of T cells responding to NY-
ESO-1 or Melan-A peptides. On the other hand, no associa-
tion between survival and the presence of T cells responding123
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rates were even higher in patients that responded to multi-
ple peptides and in patients that showed an unopposed pro-
inXammatory response. Interestingly, only CD8+ T-cell
reactivity to Melan-A correlated with survival, whereas
both CD4+ and CD8+ reactivity to NY-ESO-1 correlated
equally well with survival. In the last part of the presenta-
tion, Pawelec discussed the possible correlation between
CMV status and responsiveness to immune therapy. The
incidence of CMV seropositivity is especially high in the
elderly in whom CMV control requires a huge commitment
of immune resources. In the presented clinical trials, a cor-
relation between NY-ESO1 response in the prospective
long term survival group (>18 months) and a negative
CMV status was observed, indeed, suggesting that the mea-
surement of CMV seropositivity should be included in
future immunomonitoring.
Immunosenescence in elderly people has been shown to
be characterized in part by decreased numbers of naïve T
cells as well as decreased diversity and function of memory
T cells. As discussed by Claudia Gravekamp (New York,
NY, USA) in the Joseph Lustgarten Memorial Lecture a
novel recall approach using Listeria to selectively infect
and kill tumor cells may overcome the compromised immu-
nity. She started out by remembering Joseph Lustgarten
who sadly passed away recently, and acknowledged his sci-
entiWc contributions to cancer immunology and ageing.
This led to presentation of her own work on a Listeria-
based vaccine. Listeria infects both monocytic and granulo-
cytic myeloid derived suppressor cells (MDSC) and as
MDSC accumulate in tumors they will bring Listeria,
which is then capable of infecting and killing tumor cells
directly. Importantly, MDSC in the tumor microenviron-
ment are highly immune-suppressive and will protect Liste-
ria from clearance by immune cells. Indeed, healthy tissues
are not immune suppressed and Listeria will be eVectively
cleared. Furthermore, the Listeria used can be modiWed to
express T-cell epitopes of recall antigens, such as tetanus
toxoid (TT). As shown in mice studies, when using Liste-
ria-TT in mice pre-vaccinated with TT, tumor cells were
also killed by TT antigen-speciWc memory T cells. This
recall approach to activate T cells already present from
childhood vaccination will further overcome the needs for
naïve T cells in the response to vaccination of older
patients.
Indeed, a great number of tumor speciWc peptides have
been identiWed and post-translational modiWcations and
altered glycosylation in tumor cells shown to lead to
generation of new tumor epitopes. Victor Engelhard
(Charlottesville, VA, USA) discussed how phosphorylation of
peptides creates new tumor antigens that can provide novel
targets for immunotherapy and cancer vaccination. These
so-called phosphopeptides are formed post-translationally
by the degradation of properly folded proteins within the
cell and several phosphopeptides are upregulated in cancer.
3D analysis of MHC interactions showed that phosphopep-
tides can be recognized by T cells and can alter MHC binding
of the original peptide, thereby creating new antigens. As
presented by Ana Maria Vazquiz (Havana, Cuba), pre-
clinical and clinical trials with Racotumomab; an anti-idio-
type mAb directed against NeuGc-containing gangliosides
expressed in tumors, showed that Racotumomab reduces
lung metastases incidence in murine lung and breast carci-
nomas by increasing tumor cell apoptosis, increasing the
number of inWltrating CD4+ and CD8+ lymphocytes and
reducing the number of blood vessels. Clinical data showed
that Racotumomab is well tolerated in patients. In a ran-
domized, double blind, placebo-controlled phase II/III
eYcacy clinical trial in advanced NSCLC the intent to treat
analysis (ITT) showed a statistically signiWcant beneWt in
overall survival for the Racotumomab arm. At this point a
phase III multinational clinical trial is ongoing.
Even though vaccination may lead to induction of suc-
cessful anti-tumor immune responses, tumor escape mecha-
nisms have been shown to protect malignant cells from
immune recognition and strategies to overcome these major
obstacles to successful clinical vaccination were presented
and discussed. Barbara Seliger (Halle, Germany) addressed
the down-regulation of HLA class I molecules on tumors.
She demonstrated that impaired JAK2 expression leads to
reduced IFN- based inducibility of the expression of HLA
class I antigen processing machinery (APM) in melanoma
cell lines. Furthermore, she showed that the transcription
factor E2F1 was a central regulator of the HLA class I
APM components and, consistent with this, deregulation of
E2F1 has been observed in many cancers. As suggested by
Federico Garrido (Granada, Spain), immunotherapy
changes the tumor microenvironment which leads to HLA
class I negative metastases. Tumors with dysregulation of
HLA class I can be classiWed as either (1) soft lesions that
up regulate class I in response to therapy or (2) hard lesions
having irreversible low expression of HLA class I and
being resistant to therapy. The nature of the preexisting
HLA-class I lesions may play an important role for deter-
mining the Wnal outcome of cancer immunotherapy. Garr-
ido showed that IFN or vaccination lead to immune
selection of a subgroup of metastases with irreversible low
HLA class I expression (hard lesions).
MDSC are known to accumulate in tumors and have a
direct eVect on the suppression of tumor-reactive T-cells,
the polarization of macrophages towards a tumor-promot-
ing M2-like phenotype, and the traYcking of T cells.
Suzanne Ostrand-Rosenberg (Baltimore, MD, USA)
showed how the MDSC levels in mice could be regulated
by T cells expressing Fas Ligand (FasL). Via Fas–FasL
interactions T cells were capable of killing Fas+ MDSC in123
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T cells and MDSC. Thus, MDSC suppress T-cell activa-
tion; however, when T cells are activated they can trigger
MDSC apoptosis. Based on gene expression proWling Tho-
mas Gajewski (Chicago, IL, USA) described two categories
of metastases from advanced melanoma patients. One sub-
group had an inXamed phenotype expressing chemokines
and T-cell markers, as well as other immunoregulatory fac-
tors. Indeed, this subgroup showed the highest expression
of negative regulators such as PD-L1, Indoleamine 2,3-
dioxygenase (IDO) and FoxP3, also these metastases were
rich in CD8+ T cells. In contrast, the non-inXamed metasta-
ses lacked chemokines for T-cell migration and were T
cell-poor. Furthermore, he showed that anergic T cells in
tumor settings have surface expression of LAG3 and
CRTAM. Gajewski asked: which came Wrst? Do T cells
coming to tumors induce suppressiveness (e.g. upregulation
of PD-L1, IDO) or are tumors suppressive prior to T-cell
migration? His group’s data suggest that upregulation of
IDO and PD-L1, and recruitment of Tregs, in the tumor
microenvironment are dependent on CD8+ T cells and
therefore immune-intrinsic. As shown by Vincenzo Bronte
(Verona, Italy) expression of the CCL2-receptor; CCR2, by
T cells was essential for their intra-tumoral localization.
Reactive nitrogen species (RNS) in the tumor lead to nitra-
tion of the chemokine CCL2 resulting in decreased recruit-
ment and inWltration of T cells into murine and human
tumors. The use of a drug (AT38) inhibiting the intratu-
moral generation of RNS facilitated the invasion of tumor-
speciWc T cells into tumors after adoptive cell transfer
(ACT) with mTERT-reactive CTL in mice. Better survival
of these mice indeed suggested that targeting of RNS pro-
duction in tumors may help improve the eYcacy of cancer
immunotherapy.
Immunoregulatory cells named supporter T cells (Tsup)
were presented by Mads Hald Andersen (Herlev, Denmark)
as T cells speciWc for IDO. They can be detected in cancer
patients and healthy volunteers and have been observed in
both CD4+ and CD8+ T-cell populations. IDO-speciWc
CD8+ T cells are able to kill IDO-expressing tumor cells
and DCs. Intriguingly, IDO-speciWc CD8+ T cells can boost
T-cell immunity against other antigens in vitro as well as
reduce the level of Tregs in cultures. Thus, they seem to
overcome or delay the immune suppressive actions of the
IDO-protein when expressed by maturing APC and as a
consequence the IDO-speciWc CD8+ T cells have been thus
named. In addition to IDO, T-cell reactivity against other
immunoregulatory molecules, such as Indoleamine 2,3-
dioxygenase-2 (IDO2), heme oxygenase-1 (HO-1) and
NF-kB-inhibitor has also been observed, indicating that
self-reactive antigen-speciWc T cells recognizing immune
regulatory targets have an immune regulatory role. Sjoerd
van der Burg (Leiden, Holland) described how CD8+ and
CD4+ T cells found in TILs and tumor draining lymph
nodes (TDLN) from cervical carcinoma patients were poly-
clonal and reactive against a broad HPV antigen repertoire.
He demonstrated that soluble factors secreted by cervical
carcinomas induced IL-10-producing M2 macrophages
and, interestingly, IFN--producing CD4+ T cells could
switch M2 macrophages to M1 macrophages. This surely
suggests that boosting HPV-speciWc CD4+ Th1 immunity is
relevant in cancer therapy; however, it should be considered
that HPV-speciWc CD4+ Tregs may be induced as well
which could lead to clinical failure.
EVective cancer vaccination appears to require T-cell
immunity, however, there is still a lack of correlation
between induction of tumor responses in patients with their
clinical outcome. At the PIVAC-11 meeting new strategies
and approaches were presented addressing the issues of
identifying new tumor antigens, promoting powerful tumor
speciWc T-cell responses and immune monitoring. It has
become clear that immune escape mechanisms and immune
suppression are major obstacles to successful cancer treat-
ment and the combination of cancer vaccination with tar-
geting of the immune suppressive elements holds great
promise to future cancer treatment. To this end, it is impor-
tant to learn more about the plasticity of immune regulatory
cells and how they are induced in diVerent tumor microen-
vironments.
PIVAC-12, the next scientiWc meeting in this series, will
take place in Nottingham, UK, from 11 to 13 September, 2012.
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